The success of Sildenafil initially fueled a boom for pharma, but recent shifts present a uncertain scenario for investors. Off-patent competitors are eroding profits, and continued litigation add additional risk to https://poppieqhyo847122.goabroadblog.com/39950715/the-blue-pill-and-the-pharmaceutical-industry-a-risky-bet